清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Ianalumab in Sjögren's syndrome: what can we learn from lupus trials?

医学 系统性红斑狼疮 舍格伦综合征 皮肤病科 内科学 免疫病理学 全身性疾病 疾病
作者
Sarah Dyball,Ben Parker,Ian N Bruce
出处
期刊:The Lancet [Elsevier BV]
卷期号:400 (10355): 807-808 被引量:3
标识
DOI:10.1016/s0140-6736(22)01536-7
摘要

We congratulate Simon J Bowman and colleagues1Bowman SJ Fox R Dörner T et al.Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.Lancet. 2022; 399: 161-171Summary Full Text Full Text PDF PubMed Scopus (18) Google Scholar on the success of ianalumab in primary Sjögren's syndrome, particularly after the paucity of successful phase 2 randomised controlled trials in the condition. This trial showed an improvement in disease activity (ie, the European League Against Rheumatism [EULAR] Sjögren's Syndrome Disease Activity Index score), whereas symptom burden and health-related quality of life (ie, the EULAR Sjögren's Syndrome Patient Reported Index, the Functional Assessment of Chronic Illness Therapy-Fatigue, short form 36, and the Patient Global Assessement scale) did not show significant improvement compared with placebo. The disconnect between patient-reported and physician-reported outcomes highlights challenges in trial design that need to be considered when progressing to phase 3 trials. We note attempts in the ongoing TWINSS study to separate patients into two subgroups to finesse the phase 3 trial design (NCT03905525).Systemic lupus erythematosus and primary Sjögren's syndrome share a history of clinical trials not reaching their primary endpoint. Our personal experience of and published evidence from previous systemic lupus erythematosus trials shows that therapies often show promise in phase 2 trials that does not usually translate to success in phase 3. Not meeting the majority of the phase 2 endpoints might serve as a particular warning of the risk of therapies not working at phase 3. For example, the phase 2b trial2Wallace DJ Kalunian K Petri MA et al.Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Ann Rheum Dis. 2014; 73: 183-190Crossref PubMed Scopus (217) Google Scholar of epratuzumab showed improvements in the British Isles Lupus Assessment Group-based Composite Lupus Assessment but not in the Systemic Lupus Erythematosus Disease Activity Index (version 2K), mean corticosteroid use, and the Physician's Global Assessment, but then did not achieve the primary endpoint in two phase 3 trials. In contrast, anifrolumab met the several composite (ie, Systemic Lupus Erythematosus Responder Index-4 and the British Isles Lupus Assessment Group-based Composite Lupus Assessment) and organ-specific domains (ie, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity and joint counts) in a phase 2b trial3Furie R Khamashta M Merrill JT et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.Arthritis Rheumatol. 2017; 69: 376-386Crossref PubMed Scopus (460) Google Scholar and went on to have success in phase 3 trials, which led to its regulatory approval for moderate-to-severe systemic lupus erythematosus.4Morand EF Furie R Tanaka Y et al.Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med. 2020; 382: 211-221Crossref PubMed Scopus (386) Google Scholar, 5Furie RA Morand EF Bruce IN et al.Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.Lancet Rheumatol. 2019; 1: e208-e219Summary Full Text Full Text PDF Scopus (150) Google ScholarWith ianalumab, we suggest that careful analysis of the effect of comorbidities (eg, fibromyalgia), pre-existing damage, and study design should be examined further, and such lessons factored into the design of the phase 3 programme.SD received grant support from UCB and Eli Lilly. INB received grant support from Genzyme/Sanofi, GSK, Roche, and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, and UCB; and was a speaker for AstraZeneca, GSK, and UCB. BP received grant support from Genzyme/Sanofi and GSK; honoraria from Fresenius-Kabi and AbbVie; and was a speaker for Eli Lilly and Roche. We congratulate Simon J Bowman and colleagues1Bowman SJ Fox R Dörner T et al.Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.Lancet. 2022; 399: 161-171Summary Full Text Full Text PDF PubMed Scopus (18) Google Scholar on the success of ianalumab in primary Sjögren's syndrome, particularly after the paucity of successful phase 2 randomised controlled trials in the condition. This trial showed an improvement in disease activity (ie, the European League Against Rheumatism [EULAR] Sjögren's Syndrome Disease Activity Index score), whereas symptom burden and health-related quality of life (ie, the EULAR Sjögren's Syndrome Patient Reported Index, the Functional Assessment of Chronic Illness Therapy-Fatigue, short form 36, and the Patient Global Assessement scale) did not show significant improvement compared with placebo. The disconnect between patient-reported and physician-reported outcomes highlights challenges in trial design that need to be considered when progressing to phase 3 trials. We note attempts in the ongoing TWINSS study to separate patients into two subgroups to finesse the phase 3 trial design (NCT03905525). Systemic lupus erythematosus and primary Sjögren's syndrome share a history of clinical trials not reaching their primary endpoint. Our personal experience of and published evidence from previous systemic lupus erythematosus trials shows that therapies often show promise in phase 2 trials that does not usually translate to success in phase 3. Not meeting the majority of the phase 2 endpoints might serve as a particular warning of the risk of therapies not working at phase 3. For example, the phase 2b trial2Wallace DJ Kalunian K Petri MA et al.Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Ann Rheum Dis. 2014; 73: 183-190Crossref PubMed Scopus (217) Google Scholar of epratuzumab showed improvements in the British Isles Lupus Assessment Group-based Composite Lupus Assessment but not in the Systemic Lupus Erythematosus Disease Activity Index (version 2K), mean corticosteroid use, and the Physician's Global Assessment, but then did not achieve the primary endpoint in two phase 3 trials. In contrast, anifrolumab met the several composite (ie, Systemic Lupus Erythematosus Responder Index-4 and the British Isles Lupus Assessment Group-based Composite Lupus Assessment) and organ-specific domains (ie, Cutaneous Lupus Erythematosus Disease Area and Severity Index activity and joint counts) in a phase 2b trial3Furie R Khamashta M Merrill JT et al.Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.Arthritis Rheumatol. 2017; 69: 376-386Crossref PubMed Scopus (460) Google Scholar and went on to have success in phase 3 trials, which led to its regulatory approval for moderate-to-severe systemic lupus erythematosus.4Morand EF Furie R Tanaka Y et al.Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med. 2020; 382: 211-221Crossref PubMed Scopus (386) Google Scholar, 5Furie RA Morand EF Bruce IN et al.Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.Lancet Rheumatol. 2019; 1: e208-e219Summary Full Text Full Text PDF Scopus (150) Google Scholar With ianalumab, we suggest that careful analysis of the effect of comorbidities (eg, fibromyalgia), pre-existing damage, and study design should be examined further, and such lessons factored into the design of the phase 3 programme. SD received grant support from UCB and Eli Lilly. INB received grant support from Genzyme/Sanofi, GSK, Roche, and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, and UCB; and was a speaker for AstraZeneca, GSK, and UCB. BP received grant support from Genzyme/Sanofi and GSK; honoraria from Fresenius-Kabi and AbbVie; and was a speaker for Eli Lilly and Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
虚幻唯雪完成签到,获得积分10
27秒前
我是老大的应助被LeoAllen849采纳,获得40
31秒前
nk完成签到 ,获得积分10
32秒前
36秒前
剁辣椒蒸鱼头完成签到 ,获得积分10
38秒前
冷酷紫烟完成签到,获得积分10
57秒前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
科研通AI65的应助被海宁采纳,获得10
1分钟前
1分钟前
怕孤独的梦寒完成签到,获得积分10
1分钟前
风中黎昕完成签到 ,获得积分10
1分钟前
海宁发布了新的文献求助10
1分钟前
合适乐巧完成签到 ,获得积分10
1分钟前
shoemaker完成签到,获得积分10
1分钟前
夏纪完成签到 ,获得积分10
1分钟前
柔弱的水风完成签到,获得积分10
2分钟前
u404711发布了新的文献求助10
2分钟前
舒心鞋垫完成签到,获得积分10
2分钟前
快乐舒完成签到 ,获得积分10
2分钟前
n01W97的应助被科研通管家采纳,获得40
3分钟前
无限的水香完成签到,获得积分10
3分钟前
朴实水云完成签到,获得积分10
3分钟前
Cakoibao的应助被dianeil采纳,获得10
3分钟前
YYM完成签到 ,获得积分10
3分钟前
3分钟前
激情的盼晴完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
4分钟前
4分钟前
yanweihome完成签到 ,获得积分10
4分钟前
4分钟前
高高仰完成签到,获得积分10
4分钟前
4分钟前
缓慢忆灵完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185392
求助须知:如何正确求助?哪些是违规求助? 9574120
关于积分的说明 21834329
捐赠科研通 7782811
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481272